重组生物技术制品生产工艺变更的病毒安全性风险再评估策略

Wenbo Sai; Dongchen Jia; Hao Chen; Wei Wei

doi:10.1016/j.eng.2023.10.003

PDF(367 KB)

工程（英文） ›› 2024, Vol. 32 ›› Issue (1) : 14-17. DOI: 10.1016/j.eng.2023.10.003

观点和评述

重组生物技术制品生产工艺变更的病毒安全性风险再评估策略

作者信息 +

Strategy for Viral Safety Risk Reassessment with Changes in the Manufacturing Process of Recombinant Biotechnology Products

Author information +

History +

引用本文

EndNote

Ris (Procite)

Bibtex

导出引用

Wenbo Sai, Dongchen Jia, Hao Chen. 重组生物技术制品生产工艺变更的病毒安全性风险再评估策略. Engineering. 2024, 32(1): 14-17 https://doi.org/10.1016/j.eng.2023.10.003

参考文献

原文顺序 | 文献年度倒序 | 文中引用次数倒序

[1]	ICH Harmonised Tripartite Guideline.Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin Q5A(R1) [Internet]. Geneva: The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; 1999 Sep 23 [cited 2023 Aug 13].
[2]	ICH Harmonised Guideline.Technical and regulatory considerations for pharmaceutical product lifecycle management Q12 [Internet]. Geneva: The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; 2017 Nov 16 [cited 2023 Aug 13].
[3]	S. Chinniah, P. Hinckley, L. Connell-Crowley. Characterization of operating parameters for XMuLV inactivation by low pH treatment. Biotechnol Prog, 32 (1) ( 2016), pp. 89-97
[4]	J. Mattila, S. Curtis, Y. Webb-Vargas, E. Wilson, O. Galperina, D. Roush, et al.. Retrospective evaluation of cycled resin in viral clearance studies—a multiple company collaboration. PDA J Pharm Sci Technol, 73 (5) ( 2019), pp. 470-486
[5]	G. Bolton, M. Cabatingan, M. Rubino, S. Lute, K. Brorson, M. Bailey. Normal-flow virus filtration: detection and assessment of the endpoint in bioprocessing. Biotechnol Appl Biochem, 42 (2) ( 2005), pp. 133-142
[6]	ICH Harmonised Guideline.Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin Q5A(R2) [Internet]. Geneva: The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; 2022 Sep 29 [cited 2023 Aug 13].
[7]	P.U. Joshi, C.L. Meingast, X. Xu, M. Holstein, H. Feroz, S. Ranjan, et al.. Virus inactivation at moderately low pH varies with virus and buffer properties. Biotechnol J, 17 (2) ( 2022), p. 2100320
[8]	G. Miesegaes, S. Lute, K. Brorson. Analysis of viral clearance unit operations for monoclonal antibodies. Biotechnol Bioeng, 106 (2) ( 2010), pp. 238-246
[9]	L. Connell-Crowley, E.A. Larimore, R. Gillespie. Using high throughput screening to define virus clearance by chromatography resins. Biotechnol Bioeng, 110 (7) ( 2013), pp. 1984-1994
[10]	S. Curtis, K. Lee, G.S. Blank, K. Brorson, Y. Xu. Generic/matrix evaluation of SV40 clearance by anion exchange chromatography in flow-through mode. Biotechnol Bioeng, 84 (2) ( 2003), pp. 179-186
[11]	R. Specht, A. Schwantes.Proceedings of the 2019 Viral Clearance Symposium, Session 2:New Modalities in Chromatography and Adsorptive Filters. PDA J Pharm Sci Technol, 76 (4) ( 2022), pp. 306-314
[12]	L. Connell-Crowley, T. Nguyen, J. Bach, S. Chinniah, H. Bashiri, R. Gillespie, et al.. Cation exchange chromatography provides effective retrovirus clearance for antibody purification processes. Biotechnol Bioeng, 109 (1) ( 2012), pp. 157-165
[13]	M.R. Brown, S.A. Johnson, K.A. Brorson, S.C. Lute, D.J. Roush. A step-wise approach to define binding mechanisms of surrogate viral particles to multi-modal anion exchange resin in a single solute system. Biotechnol Bioeng, 114 (7) ( 2017), pp. 1487-1494
[14]	S. O’Donnell, G. Bolton.Proceedings of the 2019 Viral Clearance Symposium, Session 6:Virus-Retentive Filtration. PDA J Pharm Sci Technol, 76 (4) ( 2022), pp. 349-357